---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-033075"
form_type: "8-K"
ticker: "DNTH"
cik: "0001690585"
company_name: "Dianthus Therapeutics, Inc. /DE/"
filed_at: "2025-03-05T23:59:59+00:00"
generated_at: "2026-05-25T10:37:49.935270+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Director Tomas Kiselak resigns; Sujay Kango appointed to board and compensation committee

## Summary
- Tomas Kiselak resigned from Dianthus Therapeutics board effective March 4, 2025; no disagreement cited.
- Sujay Kango appointed as Class II director and member of Compensation Committee, effective March 4, 2025.
- Kango receives initial option grant of 25,000 shares vesting over three years; cash compensation of $40,000/yr (board) and $6,000/yr (committee).
- Kango will enter into a standard indemnification agreement with the company.

## SEC filing metadata
- accession: 0000950170-25-033075
- form_type: 8-K
- ticker: DNTH
- cik: 0001690585
- company_name: Dianthus Therapeutics, Inc. /DE/
- filed_at: 2025-03-05T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1690585/000095017025033075/0000950170-25-033075-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1690585/000095017025033075/dnth-20250304.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-033075
- JSON: https://secwatch.observer/filing/0000950170-25-033075.json
- Plain text: https://secwatch.observer/filing/0000950170-25-033075.txt

## Key facts
- Executive change
  Sujay Kango was appointed as Director at Dianthus Therapeutics, Inc. /DE/.
  - Action: appointed
  - Role: Director
  source text: On March 4, 2025, the Board appointed Sujay Kango as a Class II director of the Company and as a member of the Compensation Committee of the Board (the “Compensation Committee”), effective immediately after close of business on March 4, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1690585/000095017025033075/0000950170-25-033075-index.htm
- Executive change
  Tomas Kiselak resigned as Director at Dianthus Therapeutics, Inc. /DE/.
  - Action: resigned
  - Role: Director
  source text: On March 4, 2025, Tomas Kiselak, a member of the Board of Directors (the “Board) of Dianthus Therapeutics, Inc. (the “Company”), notified the Company of his resignation from the Board effective as of the close of business on March 4, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1690585/000095017025033075/0000950170-25-033075-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.